I analyze the effects of four types of medical innovation and cancer incidence on US cancer mortality rates during the period 2000–2009, by estimating difference-in-differences models using longitudinal (annual) data on ∼60 cancer sites (breast, colon, etc.). The outcome measure used is not...

This study examines the impact of pharmaceutical innovation and other factors on the survival of U.S. cancer patients during the period 1992-2003. In particular, it investigates whether cancer survival rates increased more for those cancer sites that had the largest increases in the proportion...

We analyze the association that pharmaceutical innovation had with premature mortality from all diseases in Switzerland during the period 1996-2018, and its association with hospital utilization for all diseases in Switzerland during the period 2002-2019. The analysis is performed by...